Drugs / RG1068
RG1068
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00621556 | Feb → Dec 2008 | pancreatic intraductal papillary-mucinous neoplasm | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00621283 | Feb → Dec 2008 | chronic pancreatitis, recurrent acute pancreatitis | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00620919 | Feb → Dec 2008 | chronic pancreatitis | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT00216294 | Feb 2005 → Apr 2006 | obsessive-compulsive disorder | Indiana University | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT00660335 | Mar 2008 → Oct 2009 | pancreatitis | Repligen Corporation | Completed | Met primary |
| Phase 3 | NCT00036231 | Apr 2002 → ? | autism | Repligen Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT00036244 | Apr 2002 → Jan 2004 | autism | Repligen Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG1068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00621283 ↗ |
| Known as | secretin | “RG1068 (synthetic human secretin)” NCT00660335 ↗1“RG1068 (Synthetic Human Secretin)” NCT00621283 ↗ |
| Known as | Synthetic Human Secretin | “RG1068 (Synthetic Human Secretin)” NCT00216294 ↗6“RG1068 (Synthetic Human Secretin)” NCT00621283 ↗ “RG1068 (synthetic human secretin)” NCT00660335 ↗ “RG1068 (Synthetic Human Secretin)” NCT00620919 ↗ “RG1068 (Synthetic Human Secretin)” NCT00036231 ↗ “RG1068 (Synthetic Human Secretin)” NCT00036244 ↗ “RG1068 (Synthetic Human Secretin)” NCT00621556 ↗ |
| Modality | Peptide | “RG1068 is a synthetic human secretin with a pharmacological profile very similar to that of biological and synthetic porcine secretins. Secretin is a 27-amino acid...” NCT00620919 ↗ |
| Route | Subcutaneous | “receive subcutaneous injections of RG1068 at 10 µg/kg” NCT00216294 ↗ |